BXRX Baudax Bio Inc.

2.29
-0.19  -8%
Previous Close 2.48
Open 2.47
Price To Book -2.41
Market Cap 40,235,273
Shares 17,569,988
Volume 635,337
Short Ratio
Av. Daily Volume 697,845
Stock charts supplied by TradingView

NewsSee all news

  1. Baudax Bio Announces Closing of $25 Million Public Offering of Securities

    MALVERN, Pa., March 26, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. ("Baudax" or the "Company") (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the closing of the

  2. Baudax Bio Announces Pricing of Public Offering of Common Stock and Warrants

    MALVERN, Pa., March 24, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. ("Baudax" or the "Company") (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the pricing of an

  3. Baudax Bio Announces Proposed Public Offering of Common Stock and Warrants

    MALVERN, Pa., March 23, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. ("Baudax" or the "Company") (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has

  4. Baudax Bio Signs Non-Binding Term Sheet for Debt Facility

    MALVERN, Pa., March 04, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that, as part of its overall capital financing

  5. Baudax Bio Announces FDA Approval of ANJESO™ for the Management of Moderate to Severe Pain

    ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing U.S. Commercial Launch Planned to Commence in Late April or Early May 2020 Management to Host Conference Call and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval announced February 20, 2020.
Intravenous (IV) meloxicam
Acute pain following bunionectomy surgery
Phase 1 trial to be initiated 1H 2020.
RP-1000

Latest News

  1. Baudax Bio Announces Closing of $25 Million Public Offering of Securities

    MALVERN, Pa., March 26, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. ("Baudax" or the "Company") (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the closing of the

  2. Baudax Bio Announces Pricing of Public Offering of Common Stock and Warrants

    MALVERN, Pa., March 24, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. ("Baudax" or the "Company") (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the pricing of an

  3. Baudax Bio Announces Proposed Public Offering of Common Stock and Warrants

    MALVERN, Pa., March 23, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. ("Baudax" or the "Company") (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has

  4. Baudax Bio Signs Non-Binding Term Sheet for Debt Facility

    MALVERN, Pa., March 04, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that, as part of its overall capital financing

  5. Baudax Bio Announces FDA Approval of ANJESO™ for the Management of Moderate to Severe Pain

    ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing U.S. Commercial Launch Planned to Commence in Late April or Early May 2020 Management to Host Conference Call and

  6. Baudax Bio Reports 2019 Annual Financial Results

    FDA Grants Appeal for IV Meloxicam New Drug Application PDUFA Goal Date of February 20, 2020 MALVERN, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on

  7. Baudax Bio Announces PDUFA Date for Intravenous Meloxicam

    MALVERN, Pa., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a specialty pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food and Drug

  8. Baudax Bio to Present at the Piper Jaffray 31st Annual Healthcare Conference

    MALVERN, Pa., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Baudax Bio, Inc., (NASDAQ:BXRX) a pharmaceutical company focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings,